© Borgis - Medycyna Rodzinna 3, p. 75-79
Aleksandra Krause, Paulina Górska, Janusz Ślusarczyk
Adiuwanty – substancje stymulujące odpowiedź immunologiczną – część I
Adjuvants – substances stimulating immune response. Part I
Zakład Badania Surowic i Szczepionek Państwowego Zakładu Higieny w Warszawie
Kierownik Zakładu: prof. dr hab. med. Janusz Ślusarczyk
Summary
Adjuvants are substances which enhance humoral as well as cellular immunological response to an antigen. Since more than 60 years they are used as immunostimulators in different preparations administered to acquire active immunization. Many different experiments proved that adjuvants improve effectiveness of vaccines and allergen preparations, nonetheless absolutely safe adjuvants still does not exist. Adjuvants may cause different adverse reactions, i.e. local acute or chronic inflammation, angioedema, immunosuppression, and even anaphylactic shock. Therefore new adjuvant formulas, more effective and safer are being developed. In the first part of the paper entitled "Adjuvants – substances stimulating immunological response” effects and mechanisms of action of adjuvants currently used, as well as experimental ones are described. Main groups of these substances were characterized with regard to their physico-chemical properties, such as mineral compounds, emulsions and saponines, many different adjuvant formulas were also specified, among others aluminum compounds, SAF, MF59, Quil A, QS-21, or immunostimulating complex ISCOMs.
Key words: adjuvants, vaccines, immune response, immunostimulator, antigen presenting cell (APC)
Piśmiennictwo
1. Gupta R.K., et al.: Adjuvants – a balance between toxicity and adjuvanticity. Vaccine 1993; 11, 3: 293-306. 2. Chodaczek G.: Adiuwanty jako czynniki podnoszące skuteczność szczepionek. Postępy Hig. Med. Dośw., 2004; 58: 47-59. 3. Fiejka M., Aleksandrowicz J.: Perspektywy zastosowania w szczepionkach nowych adiuwantów. W: Ślusarczyk J. Szczepienia i Szczepionki Teraźniejszość i Przyszłość. Referaty wygłoszone podczas Konferencji Naukowej Polskiego Towarzystwa Epidemiologów i Lekarzy Chorób Zakaźnych. Bydgoszcz, 16-18.09.1998. SmithKline Beecham Polska Sp. z o.o. 1999, 167-179. 4. Dzierzbicka K., Kołodziejczyk A.M.: Adiuwanty – niezbędne składniki szczepionek nowej generacji. Postępy Biochemii 2006; 52, 2: 204-211. 5. Newman M.J.: Vaccines adjuvant. Expert Opinion on Therapeutic Patents 2000; 10: 279-314. 6. Kenney R.T., Edelman R.: Survey of human – use adjuvants. Expert Rev Vaccines 2003; 2: 167-188. 7. Górska P.: Adiuwanty oraz substancje konserwujące i stabilizujące zawarte w szczepionkach. W: Magdzik W., Naruszewicz-Lesiuk D., Zieliński A. Wakcynologia (2-gie wydanie. Bielsko-Biała: α-medica press; 2007, 68. 8. Aucouturier J., et al.: Adjuvants designed for veterinary and human vaccines. Vaccine 2001; 19: 2666-2672. 9. Allison A.C., Byars N.E.: Adjuvant formulations and their mode of action. Semin Immunol 1990; 2, 5: 369-74. 10. Podda A., Del Giudice G.: MF59 – adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003; 2, 2: 197-203. 11. Singh M., O´Hagan D.: Advances in vaccine adjuvants. Nat Biotechnol 1999; 17, 11: 1075-81. 12. Garcon N., et al.: Development of RTS, S/AS02: a purified subunit – based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2003; 2, 2: 231-238. 13. Skene C.D., Sutton P.: Saponin-adjuvanted particulate vaccines for clinical use. Methods 2006; 40, 1: 53-59. 14. Garcon N., et al.: Development of RTS, S/AS02: a purified subunit – based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines 2003; 2: 231-238. 15. Estrada A., et al.: Isolation and evaluation of immunological adjuvant activities of saponins from Polygala senega L. Comp. Immunol. Microbiol. Infect. Dis., 2000; 23, 1: 27-43. 16. Pascual D.M., et al.: Adjuvants: Present regulatory challenges. Vaccine 2006; 24S2: S2/88-S2/89. 17. Sanders M.T., et al.: ISCOM-based vaccines: the second decade. Immunol. Cell. Biol., 2005; 83, 2: 119-128. 18. Pearse M.J., Drane D.: ISCOMATRIX adjuvant for antigen delivery. Adv. Drug. Deliv. Rev., 2005; 57, 3: 465-74. 19. Myschik J., et al.: On the preparation, microscopic investigation and application of ISCOMs. Micron. 2006; 37, 8: 724-34. 20. Smith R.E., et al.: Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J. Immunol., 1999; 162: 5536-5546.
otrzymano/received: 2007-07-06
zaakceptowano/accepted: 2007-08-10
Adres/address:
*Aleksandra Krause
Pracownia Immunochemii Zakład Badania Surowic i Szczepionek Państwowy Zakład Higieny Instytut Naukowo-Badawczy
ul. Chocimska 24, 00-791 Warszawa
tel. 0-22 542-13-47
e-mail: akrause@pzh.gov.pl
